When was ProQR Therapeutics founded?

ProQR Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is ProQR Therapeutics located?

ProQR Therapeutics is headquartered in Leiden, Netherlands.

How many employees does ProQR Therapeutics have?

As of Jul 31, 2026, the latest employee count at ProQR Therapeutics is 202.

Is ProQR Therapeutics a funded company?

ProQR Therapeutics is a funded company, having raised a total of $58M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2013.

When was the latest funding round of ProQR Therapeutics?

ProQR Therapeutics' latest funding was a $***** Post IPO round on Jul 14, 2020, with participation from 1 investor.

Where does ProQR Therapeutics rank among its competitors?

ProQR Therapeutics ranks 20th amongst 642 active competitors, of which 229 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of ProQR Therapeutics?

ProQR Therapeutics' top competitors include Alnylam, Spark Therapeutics and BioMarin Pharmaceutical. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

ProQR Therapeutics - 2026 Company Profile, Funding & Competitors

Company Details

Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders. The company has designed therapeutic candidates to specifically target and repair the defective messenger RNA, (mRNA). Their proprietary technology known as Axiomer involves the use of single-stranded RNA-based oligonucleotides, which act as guide sequences to repair (single nucleotide changes to RNA) the targeted abnormal mRNA. The product pipeline includes QR-110, for Leber’s congenital amaurosis patients, QR-421 for mediated retinitis pigmentosa and Usher syndrome, QR-1123 for retinal mediated retinitis pigmentosa.

Website: www.proqr.com/
Social

Key Metrics

Founded Year

2012

Location

Leiden, Netherlands

Stage

Public

Total Funding

$58M in 6 rounds

Latest Funding Round

Post IPO, Jul 14, 2020, $*****

Investors

Sofinnova Partners & 8 more

Ranked

20^th among 642 active competitors

Employee Count

202 as on Jul 31, 2026

Similar Companies

Alnylam & 802 more

Exit Details

Public

View ProQR Therapeutics' full profile

ProQR Therapeutics got listed on Sep 18, 2014.

Click here to take a look at ProQR Therapeutics's IPO in detail

ProQR Therapeutics has raised a total funding of $58M over 6 rounds. Its first funding round was on 2013. Its latest funding round was a Post IPO round on Jul 14, 2020 for $*****. 1 investor participated in its latest round. ProQR Therapeutics has 9 institutional investors.

Here is the list of recent funding rounds of ProQR Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 14, 2020	7850132	Post IPO	5919851	2910871	1385944	3131098
Oct 01, 2018	6756913	Grant (prize money)	1595360	4890911	7745183	Europa
Feb 13, 2018	5631891	Grant (prize money)	2323595	4578574	3818409	Blindness.org

Access funding benchmarks and valuations. Sign up today!

View details of ProQR Therapeutics's funding rounds and investors

ProQR Therapeutics' employee count trend

ProQR Therapeutics has 202 employees as of Jul 26. Here is ProQR Therapeutics's employee count trend over the years:

Employee count trend for ProQR Therapeutics

Uncover ProQR Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ProQR Therapeutics include Alnylam, Spark Therapeutics and BioMarin Pharmaceutical. Here is the list of Top 10 competitors of ProQR Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	MPM Capital, Temasek & 7 others	72/100
4th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
5th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Xontogeny & 7 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Adage Capital Management, F-Prime Capital ... & 10 others	69/100
9th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
10th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
20th	ProQR Therapeutics 2012, Leiden (Netherlands), Public	Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders	$58M	Gilde Healthcare, Foresite Capital & 7 others	61/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on ProQR Therapeutics's competitors? Click here to see the top ones

ProQR Therapeutics has made no investments or acquisitions yet.

Media has covered ProQR Therapeutics for a total of 22 events in the last 1 year, 10 of them have been about company updates and 2 about people movement.